Evidence map›Paper›PMID 42010180›Full record

ReviewEMBO reports2026

Breaking barriers: how cytomegaloviruses manipulate myeloid cells to invade tissues.

Agnibesh Dey, Vitka Gres, Alina Nelipovich, Philipp Kolb, Roland Immler, Zsolt Ruzsics, Katrin Kierdorf, Philipp Henneke, Sebastian Baasch

Abstract readReview
In one paragraph

Review in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Agnibesh DeyInstitute for Infection Prevention and Control, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0009-0005-9948-9778
Vitka GresInstitute for Infection Prevention and Control, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Alina NelipovichInstitute for Infection Prevention and Control, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Philipp KolbInstitute of Virology, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0001-7935-217X
Roland ImmlerInstitute of Cardiovascular Physiology and Pathophysiology, Biomedical Center, Ludwig-Maximilians-Universität (LMU) München, Planegg-Martinsried, Germany.ORCID 0000-0002-4086-7528
Zsolt RuzsicsInstitute of Virology, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Katrin KierdorfInstitute for Infection Prevention and Control, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Philipp Henneke *Institute for Infection Prevention and Control, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0001-7314-7984
Sebastian Baasch *Institute for Infection Prevention and Control, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. sebastian.baasch@uniklinik-freiburg.de.ORCID 0000-0003-4378-3474

Funding

Deutsche Forschungsgemeinschaft (DFG) 256073931Deutsche Forschungsgemeinschaft (DFG) 259373024Deutsche Forschungsgemeinschaft (DFG) 390939984Deutsche Forschungsgemeinschaft (DFG) 441891347Deutsche Forschungsgemeinschaft (DFG) 491676693Deutsche Forschungsgemeinschaft (DFG) 544402801Deutsche Forschungsgemeinschaft (DFG) KO6815/1-11University of Freiburg, Faculty of Medicine Hans A. Krebs Medical Scientist Program
6 · The paper itself

Abstract

Cytomegaloviruses are highly adapted to their hosts through millions of years of co-evolution. Most human (H)CMV infections occur early in life when the virus enters via the mucosal surfaces of the respiratory or gastrointestinal tract. These infections are usually asymptomatic, but coincide with critical phases of immune development, shaping long-term host immunity. In rare but clinically significant cases, CMV can invade protected sites, such as the central nervous system, leading to symptomatic disease. As the most abundant immune cells at barrier sites, myeloid cells support all stages of the viral life cycle: replication, dissemination, and latency. During the perinatal period, the myeloid compartment undergoes profound changes, including macrophage maturation, monocyte influx, and functional adaptation. CMV may exploit these developmental transitions to establish infection and to cross tissue barriers. This review discusses how CMV manipulates myeloid immune cells to establish postnatal infection, particularly via the respiratory tract, and explores strategies by which CMVs breach the placental barrier and access the fetal brain. The review integrates evidence from multiple CMV species, with emphasis on human and mouse data.

Indexed as

CytomegalovirusCytomegalovirus InfectionsMyeloid CellsAnimalsFemaleHost-Pathogen InteractionsHumansPlacentaPregnancy

Identifiers

PMID42010180
PMCPMC13171928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.